Clinical Trial Update: Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05% [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating adrenal suppression potential and pharmacokinetics of halobetasol lotion 0.05% in plaque psoriasis was terminated with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Halobetasol lotion 0.05% (halobetasol)

Snippet

Sponsor: Sun Pharmaceutical Industries Limited | Conditions: Plaque Psoriasis | Phase 4 | Status: TERMINATED | Results posted: 2021-12-07